What Impacted Hexo (TSX:HEXO) Stock This Month?

Has Hexo Stock bottomed out after a 33% decline in October 2019?

| More on:
Man holding magnifying glass over a document

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Shares of Canadian marijuana company Hexo (TSX:HEXO)(NYSE:HEXO) have been volatile, to say the least. The stock is trading at $3.52, which is 70% below its 52-week high. We saw that the stock was decimated on October 10 when it lost 23% after providing preliminary fiscal fourth-quarter 2019 (ending in July) estimates and withdrawing its outlook for fiscal 2020.

Hexo launched a product to take on the illegal market

I had identified the impact of cannibalization from Canada’s illegal marijuana market as a major threat for publicly listed cannabis stocks, including Hexo. The illegal market accounts for 40% of total marijuana sales in Canada due to lower product prices. This is resulting in high inventory levels for the legal players.

Last week, Hexo launched Original Stash, a value brand priced at $4.49 per gram. Hexo believes that several buyers are unaware that they are purchasing products from illegal websites and aims to educate the consumers. Will this move help to shift cannabis sales away from the illegal market and result in incremental sales for Hexo?

Cannabis 2.0: A key driver?

Last year, Hexo partnered with Molson Coors Canada to form a joint venture (JV). The two companies are eyeing opportunities in the non-alcoholic, cannabis-infused beverages vertical. The JV will start selling a variety of drinks by the end of 2019.

Canada legalized cannabis-infused edibles, vapes, and concentrate products on October 17, 2019. Hexo and Molson Coors will also look to expand in the U.S. where these products are already legal.

According to a Deloitte report, the alternative cannabis market is estimated at $2.7 billion annually. Cannabis extract-based products including edibles will lead the alternative marijuana market and account for about $1.6 billion in sales.

The report states, “11% of Canadians already consume cannabis edibles and other alternative products, and 13% of Canadians are expected to buy them, as edibles and other alternative products that offer a more discreet and accessible way to consume cannabis and avoid any stigma surrounding smoking cannabis.”

Deloitte further claimed that around 25% of Canadians are likely to consume cannabis edibles and related products, which will create new growth opportunities in this space. Though these products have been legalized, companies and consumers will have to wait till December 16 for retail purchase.

Cannabis is a highly regulated industry, and the framework for edible sales will continue to evolve over the next few months. Deloitte expects the global cannabis market to grow from $100 billion in 2019 to $194 billion in 2025.

Uncertainty over vaping products

Hexo stock fell 5.5% on October 18 after a New York Times article reported that vaping giant Juul Labs has suspended e-commerce sales of flavoured e-cigarettes. The Food and Drug Administration has accused Juul of misguiding consumers as the latter advertised its products as a safe substitute for cigarettes.

The vaping products have taken a massive hit in recent times after multiple deaths in the U.S. were attributed to vapes, and this scandal sent cannabis stocks significantly lower in September, Now, the latest announcement by Juul further dented these companies.

Marijuana companies were hoping for cannabis 2.0 to drive stock prices to record highs. Instead, Hexo and peers are trading at 52-week lows. Most cannabis companies have invested heavily in research and development of vape products. But now they might be impacted by tepid demand.

Will Hexo stock rebound heading into 2020? Analysts remain bullish and have a 12-month target price of $6.26, which is 74% above its current price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool owns shares of Molson Coors Brewing. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »